Pharmacokinetic study of infusional valspodar

Journal of Clinical Pharmacology

Volumn 42, Issue 4, 2002, Pages 412-418

  Ma, Margaret K ^a,b   McLeod, Howard L ^a,b   Westervelt, Peter ^a,b   Fracasso, Paula M ^a,b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b USA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A; PACLITAXEL; VALSPODAR;

ADULT; AGE; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; BODY WEIGHT; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARTMENT MODEL; CONTINUOUS INFUSION; DRUG CLEARANCE; DRUG METABOLISM; FEMALE; GENDER; HUMAN; MALE; PHASE 1 CLINICAL TRIAL;

EID: 0036202455     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/00912700222011463     Document Type: Article

References (42)

1. Absence of the mdr1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A
2. Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833
3. Expression of a multidrug-resistance gene in human tumors and tissues
4. Co-administration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patients
5. Coadministration of cyclosporine strongly enhances the oral bioavailability of docetaxel
6. Enhanced oral absorption and decreased elimination of paclitaxel in mice cotreated with cyclosporin A
7. A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma
8. Verapamil reversal of doxorubicin resistance in multidrug-resistant human myeloma cells and association with drug accumulation and DNA damage
9. A pilot study of quinidine and epirubicin in the treatment of advanced breast cancer
10. Adequate tumour quinidine levels for multidrug resistance modulation can be achieved in vivo
11. Intrinsic drug resistance in human kidney cancer is associated with expression of a human multidrug-resistance gene
12. Clinical trials of modulation of multidrug resistance: Pharmacokinetic and pharmacodynamic considerations
13. Resistance modification by PSC-833, a novel non-immunosuppressive cyclosporin
14. Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance
15. Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance
16. Phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer
17. Reversal of multidrug resistance by SDZ PSC 833, combined with VAD (vincristine, doxorubicin, dexamethasone) in refractory multiple myeloma: A phase I study
18. Phase I study of paclitaxel in combination with a multidrug resistance modulator, PSC 833 (valspodar), in refractory malignancies
19. Treatment of poor prognosis AML patients using PSC833 (valspodar) plus mitoxantrone, etoposide, and cytarabine (PSC-MEC)
20. Phase I/II study of the P-glycoprotein modulator PSC 833 in patients with acute myeloid leukemia
21. Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: Detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy
22. Modulation of multidrug-resistant multiple myeloma by cyclosporin
23. Coadministration of oral cyclosporin A enables oral therapy with paclitaxel
24. Initial pharmacokinetics and bioavailability of PSC 833, a P-glycoprotein antagonist
25. Optimizing the absorption of valspodar, a P-glycoprotein modulator, part I: Selecting an oral formulation and exploring its clinical pharmacokinetics/dynamics
26. Physiologically based pharmacokinetic study on a cyclosporin derivative, SDZ IMM 125
27. A nonlinear mixed-effects pharmacokinetic model comparing two formulations of cyclosporin in stable renal transplant patients
28. Dose-dependent pharmacokinetics of cyclosporin A in rats: Events in tissues
29. A program package for simulation and parameter estimation in pharmacokinetic systems
30. Efflux of rhodamine from CD56+ cells as a surrogate marker for reversal of P-glycoprotein-mediated drug efflux by PSC 833
31. Effect of P-glycoprotein modulation on the clinical pharmacokinetics and adverse effects of morphine
32. Pharmacologic interactions between the resistance-modifying cyclosporine SDZ PSC 833 and etoposide (VP 16-213) enhance in vivo cytostatic activity and toxicity
33. Phase I dose-finding and pharmacokinetic study of paclitaxel and carboplatin with oral valspodar in patients with advanced solid tumors
34. Parallel phase I studies of daunorubicin given with cytarabine and etoposide with or without the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age or older with acute myeloid leukemia: Results of Cancer and Leukemia Group B Study 9420
35. The multidrug resistance modulator valspodar (PSC 833) is metabolized by human cytochrome P450 3A: Implications for drug-drug interactions and pharmacological activity of the main metabolite
36. Gender-related differences in pharmacokinetics and their clinical significance
37. Gender-specific effects on verapamil pharmacokinetics and pharmacodynamics in humans
38. Gender differences in pharmacokinetics and pharmacodynamics
39. An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation
40. Metabolite-intermediate complexation and inhibition of microsomal CYP3A in rat liver by diltiazem
41. The P-glycoprotein antagonist PSC 833 increases the plasma concentrations of 6alpha-hydroxypaclitaxel, a major metabolite of paclitaxel
42. Phase I study of infusional paclitaxel in combination with the P-glycoprotein antagonist PSC 833